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Abstract 
BACKGROUND: Saccharomyces cerevisiae var. boulardii is the only yeast species with 
probiotic properties. It is considered to have therapeutic significance in gastro-intestinal 
disorders. In this paper, a comparative physiological study between this yeast and 
Saccharomyces cerevisiae (BY4742) was performed by evaluating two prominent traits of 
probiotic species, responses to different stress conditions and antioxidant capacity. A global 
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metabolite profile was also developed in order to identify which therapeutically important 
secondary metabolites are produced.  
RESULTS: S. cerevisiae var. boulardii showed no significant difference in growth patterns but 
greater stress tolerance when compared with S. cerevisiae. It also demonstrated a 6-10-fold 
greater antioxidant potential (judged by the DPPH assay), with 70-fold higher total phenolic 
content and 20-fold higher total flavonoid content in the extracellular fraction. These features 
were clearly differentiated by principal component analysis and further elucidated by metabolite 
profiling. The extracellular fraction of the S. cerevisiae var. boulardii cultures was found to be 
rich in polyphenolic metabolites viz. vanillic acid, cinnamic acid, phenyl ethyl alcohol (rose oil), 
erythromycin, amphetamine and vitamin B6 which results in the antioxidant capacity of this 
strain. 
CONCLUSION: This study presents a new perspective of differentiating the two genetically 
related strains of yeast, Saccharomyces cerevisiae and Saccharomyces cerevisiae var. boulardii 
by assessing their metabolome fingerprints. In addition to the correlation of the phenotypic 
properties with the secretory metabolites of these two yeasts, the work also emphasizes the 
potential to exploit S. cerevisiae var. boulardii in the industrial production of these metabolites. 
 
Keywords: Saccharomyces cerevisiae var. boulardii NCYC 3264, probiotic, Saccharomyces 
cerevisiae BY4742, stress-tolerance, antioxidant capacity, global metabolite profiling 
Introduction 
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Saccharomyces cervesiae var. boulardii, has been used as an adjunctive therapy for treatment of 
infectious gastroenteritis or in the prevention and cure of antibiotic associated diarrhea (AAD). It 
was isolated from the skin of lychee and mangosteen in Indochina and has gained popularity as 
an alternative remedy in Europe, Africa, and South America 1, 2 for AAD, acute diarrhea in 
children,  traveler’s diarrhea and irritable bowel syndrome 3, 4.  
Activities of S. cerevisiae var. boulardii include modification of host-signalling pathways 
involved in inflammatory and non-inflammatory intestinal diseases 5, inhibition of bacterial 
toxins and trophic effects on the intestinal mucosa 3. In these studies, researchers have carried 
out experiments on crude extracts of S. cerevisiae var. boulardii to assess its anti-inflammatory, 
antitoxin 6 and anti-proliferative 7 properties. 
However, the taxonomic characterization of S. cerevisiae var. boulardii has been controversial. 
Some groups have reported this yeast to be a separate species from S. cerevisiae on account of its 
therapeutic value, lack of ability to produce ascospores and its apparent inability to utilize 
galactose 8, 9. Interestingly, a later study by McCullough et al reported that S. cerevisiae var. 
boulardii is capable of utilizing galactose 10. Based on nuclear DNA (nDNA)-nDNA 
reassociation data, Cardinali and Martini located this yeast outside the sensu stricto S. cerevisiae 
cluster 11. On the contrary, Molnar et al found that S. cerevisiae var. boulardii and the type 
strains of S. cerevisiae shared the same profile in a Random Amplified Polymorphic DNA – 
Polymerase Chain Reaction (RAPD-PCR) analysis 12. However, another study was able to 
distinguish between the two strains using this method 13. Although, McCullough et al concluded 
that Restriction Fragment Length Polymorphism of the PCR-amplified intergenic transcribed 
spacer regions (ITS1-5.8S rDNA-ITS2) was not capable of differentiating S. cerevisiae var. 
boulardii from S. cerevisiae 1. In another study, microsatellite length polymorphism of clinical 
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isolates, laboratory strains and industrial strains of S. cerevisiae resulted in a distinct pattern of S. 
cerevisiae var. boulardii, which could be distinguished from S. cerevisiae 14. Comparative 
genome hybridization (CGH) and other physiological analyses revealed that S. cerevisiae var. 
boulardii strains differ significantly from laboratory strains of S. cerevisiae at both the genomic 
and physiological levels with regard to sporulation, individual chromosome and gene copy 
numbers, ability for pseudohyphal switching and survival at low acid pH. The latter two features 
have a direct bearing on the probiotic nature of S. cerevisiae var. boulardii 15.  
Apart from the molecular typing techniques, the local stress responses of probiotics entering the 
gastrointestinal tract against factors like variations in temperature and pH, presence of gut 
enzymes, bile salts and organic acids are able to distinguish the phenotypic attributes of this 
yeast.  These responses are complex processes involving the production of number of 
metabolites, intermediates, proteins and enzymes at a different level or with different activity 
compared to those observed before stress exposure. Evidence of heat shock proteins, osmotic 
shock related proteins, glutathione and thioredoxin playing vital role in protection and repair of 
damaged cell components and induced levels of enzymes as a response of re-organised metabolic 
flux in response to stress exposure has been well-documented in yeast 16.  
While over half of the last century was spent in commercial application of S. cerevisiae var. 
boulardii whole yeast formulations in treatment of diarrhea, and scientific interests on its modus 
operandi for therapeutic use 17, not much research has been channeled into exploring the 
presence of biomolecules such as metabolites or polypeptides and possibility of their potential 
industrial applications. In this study, we aimed to compare two related yeast (S. cerevisiae var. 
boulardii and S. cerevisiae) by characterising both the strains with particular reference to the 
probiotic and antioxidant properties of the former.  S. cerevisiae was chosen for this comparison 
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because it is extremely well characterised biochemically and genetically. For example, the 
genome of this organism is essentially fully determined 18.  This study has also identified which 
biomolecules are present in the extracellular and intracellular extracts of these two yeasts.  
 
Materials and methods 
Strains, media and Chemicals 
YPD broth and separate media ingredients (e.g. yeast extract, dextrose, peptone and agar) were 
purchased from Difco™ BD Biosciences, USA. All other chemicals and solvents were purchased 
from Sigma-Aldrich Co., India. S. cerevisiae var. boulardii NCYC 3264 was procured from 
National Collection of Yeast Cultures (NCYC, Norwich, United Kingdom). The S. cerevisiae 
S288c-derived laboratory strain BY4742 (MATα his3Δ, leu2Δ, lys2Δ, ura3Δ) was a gift from 
Dr. Himanshu Sinha’s laboratory (Department of Biological Sciences, Tata Institute of 
Fundamental Research, India).Culture growth conditions 
 
Yeast starter cultures (5 ml) were grown overnight in a rotary shaker (200 rpm) at 30 °C in 
YEPD medium containing 1% (w/v) yeast extract, 2% (w/v) peptone, and 2% (w/v) glucose. 
Overnight cultures were diluted to OD600 = 0.1 and inoculated in YEPD broth filled wells in 
microtitre plates. Plates were incubated at 30 °C with shaking. For anaerobic growth, wells were 
overlaid with paraffin oil and incubated without shaking at 30 °C 19. Growth curves were 
generated by sampling and reading the OD600 value after every 15mins until the cultures reached 
stationary phase using Freedom Evo 75 liquid handling and robotics station (Tecan®, 
Switzerland) equipped with a microplate reader. The maximum specific growth rate (k) was 
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calculated by plotting the OD600 values vs time fitted to the logistic growth equation in GraphPad 
Prism 6.0 (GraphPad Software Inc, CA, USA) as follows: 
OD=ODmaxOD0/((ODmax-OD0) exp(-kt) +OD0) 
Where k is the maximum specific growth rate constant, t is the time taken in the exponential 
phase of the growth curve, OD0 and ODmax are the optical densities at t = 0 and t = tmax 
(stationary phase) respectively. The optimum doubling time (td) was calculated as td = loge2/k. 
 
In vitro stress tolerance tests mimicking gastro-intestinal environment  
Yeast cultures (OD600 = 1.0) were heat shocked by shifting incubation temperatures from 30°C to 
37°C (normal body temperature), 39°C (fever condition) and 45°C (an extreme heat stress) in 
YEPD medium for 1 h. Aliquots were collected after 0, 10, 20, 30, 40, 50 and 60 min of 
incubation and the cell viability was determined microscopically by using a Neubauer chamber 
and vital staining with methylene blue 20. For experiments on simulated gastro-intestinal stress, 
overnight cultures (OD600 = 1.0) were harvested by centrifugation at 3000g for 5 min, washed 
with distilled water once, and incubated at 37 °C for 1 h in (i) a simulated gastric environment 
constituted by an aqueous solution containing 3 g/L pepsin (3200–4500 U/mg) and 5 g/L NaCl, 
pH 2.0 21, (ii) a simulated intestinal environment aqueous solution containing 1 g/L pancreatin 
(903 U/mg) and 5 g/L NaCl, pH 8.0, and (iii) exponentially grown yeast cells were diluted to an 
OD600 of 1.0 and 5 μL of this dilution was used to spot-inoculate solid YPD medium 
supplemented with 0.25%, 0.5%, 0.75% and 1% w/v concentrations of bile salts. Plates were 
visualized after 48 h at 30 °C and 37 °C.  
 
 
Preparation of cell free extract (CFE) and ethyl-acetate fraction (EAF) 
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Sterile YPD broth (pH 6.5±0.2 at 25°C) was inoculated with 1 % (V/V) of the overnight grown 
culture of the two strains of yeast, S. cerevisiae var boulardii NCYC 3264 and S. cerevisiae 
BY4742 and incubated at 30 °C for 16-18 h approximately until the same stage of growth (mid-
log phase). The overnight cultures were subjected to centrifugation at 5000g for 5 min at 4 °C. 
The supernatant was used as the CFE for assessing the total phenolic content (TPC), total 
flavonoid content (TFC) and the antioxidant capacity assays. A fraction of the supernatant was 
also extracted using ethyl acetate at 1:3 ratio (v/v) for 3 h agitation followed by filtration and 
concentration at 50°C maintained in water bath for 60 min in vacuo using a rotavac. The dried 
solute was resuspended in 40% ethanol and recovered from rotavac.  
 
Evaluation of the antioxidant potential  
 
Total phenolic content (TPC): The total polyphenolic content was determined colorimetrically 
using the Folin-Ciocalteau (FC) method according to Singleton et al. 22 with some modifications. 
The test sample (0.5 ml) was mixed with 0.2 ml of FC reagent and allowed to stand for 10 min, 
then 0.6 ml of 20% (w/v) sodium carbonate was added and mixed. The reaction mixture was 
incubated at 40 °C for 30 min. Absorbance of the reaction mixture was measured at 765 nm 
using UV/VIS spectrophotometer (Shimadzu Inc., Japan). Gallic acid was used as standard to 
construct the calibration curve (Pearson’s correlation coefficient: R2 = 0.994) and the total level 
of phenolics for each sample was expressed as milligram gallic acid equivalents per gram of 
extract (mgGAE.g-1). 
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Total flavonoid content (TFC): Total flavonoid content was determined by using the aluminium 
chloride colorimetric method as described by Willet 23 with some modifications. Aqueous 
ethanol extracts (0.5 mL), 10% (w/v) aluminium chloride (0.1 mL), 1 M potassium acetate (0.1 
mL) and distilled water (4.3 mL) were mixed. After incubation at room temperature for 30 min, 
the absorbance was measured at 415 nm using a using UV/VIS spectrophotometer (Shimadzu 
Inc., Japan). Quercetin was used as the standard and a calibration curve (Pearson’s correlation 
coefficient:R2 = 0.986) was constructed. Total flavonoid content was expressed as milligram 
quercetin equivalents per gram extract (mg QE. g-1). 
 
DPPH (1,1-diphenyl-2-picrylhydrazyl) free radical scavenging ability: The hydrogen atom or 
electron-donation ability of the corresponding extracts was measured from the bleaching of a 
purple-coloured methanol solution of DPPH 24. The antioxidant activity of the extracts, on the 
basis of the scavenging activity of the stable 1,1-diphenyl-2- picrylhydrazyl (DPPH) free radical, 
was determined by the method described by Dan et al  25 with some modifications. Briefly, an 
aliquot of 1 ml of 0.1 mM DPPH solution in ethanol and 0.5 ml of extract were mixed. The 
mixture was shaken vigorously followed by incubation at room temperature for 30 min in the 
dark. The absorbance (Abs) was measured at 517 nm. Butylated hydroxytoluene (BHT) was used 
as positive control and DPPH mixture without any sample served as blank. Percentage of 
inhibition (I %) of DPPH radical was determined using formula as below:  
 
I% = [Abs(blank) – Abs(sample) ]/Abs(blank) x 100 
 
Trolox equivalent antioxidant capacity assay (TEAC): Experiments were carried out according to 
Biskup et al 26. 2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) 
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and potassium persulfate (K2S2O8) were dissolved in distilled water to prepare the ABTS radical 
solution with a final concentration of 7 mM ABTS and 2.45 mM K2S2O8 followed by incubation 
in the dark at room temperature for 12-16 h before use in order to produce ABTS radical 
(ABTS•+) . The solution was diluted with distilled water to an absorbance of 0.7 ± 0.2 at 734 nm 
prior to use. Trolox (6-hydroxy- 2,5,7,8-tetramethylchroman-2- carboxylic acid) was used as 
standard. Working standard concentrations from 0-20 mM and extracts were added to diluted 
ABTS•+ solution and absorbance was measured 6 min after mixing at 734nm. ABTS•+ radical 
inhibition was expressed as µM Trolox equivalent antioxidant capacity (TEAC).  
 
Global metabolite profiling  
This method was carried out according to the protocol by Villas-Bôas et al 27 with slight 
modifications.  
Sample Preparation: Yeast cultures (5 ml) were grown under laboratory conditions (aerobic, 30 
°C) until mid-log phase (OD600 = 0.5) were quenched with 20 ml of 60% (v/v) methanol – buffer 
(PIPES 3 mM, EDTA 3 mM, pH 7.0) solution at -40 °C, resulting in a final methanol 
concentration of 50% (v/v), followed by centrifugation at 770g for 20 min at -20 °C to separate 
the biomass. The biomass concentration was measured between 0.7 – 1.0 g cell dry weight per 
litre (CDW l-1). Aliquots of the supernatant were evaporated to dryness under vacuum using a 
vacuum centrifuge (Eppendorf™, Germany) and stored as the extracellular fraction at -80 °C 
until the derivatisation step. Pellet was further treated for overall intracellular metabolite 
extraction i.e. amino acids, organic acids, nucleotides, peptides, sugars, sugar alcohols and sugar 
phosphates by chloroform : methanol : buffer (CMB) extraction 27 and fatty acids by pure 
methanol extraction 28. CMB extraction was carried out by resuspending the pellet in 5 ml cold 
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chloroform (−40 °C) followed by addition of 2.5 ml cold methanol (−40 °C) and 2ml ice-cold 
buffer (PIPES, 3 mM; EDTA, 3 mM; pH 7.2) sequentially under manual shaking. The 
suspension was agitated vigorously at 300 r.p.m on a platform shaker for 45 min at 4 °C. 
Separation of the chloroform and the aqueous phase was induced by centrifugation (770g, 20 
min, −20°C). The upper aqueous phase, containing the polar metabolites from the intracellular 
fraction, was collected without disturbing the pellet of the cell debris on top of the lower 
chloroform phase (lipophilic metabolites). A second extraction step was repeated and the extract 
was pooled with the upper aqueous phase in order to increase the concentration of the polar 
metabolites. Pellet was further extracted with 2.5ml pure methanol followed by freezing in liquid 
nitrogen for 10mins. The frozen suspension was thawed in an ice-bath and centrifuged at 770g 
for 20 min at −20 °C. Supernatant was collected and pooled with a second extract. Extracts 
(supernatants) of the intracellular fractions were evaporated to dryness using a vacuum 
centrifuge (Eppendorf™, Germany) and stored at -80 °C until the derivatisation step. 
Derivatisation: Methyl chloroformate (MCF) - alkylation derivatisation was carried out 
according to Villas-Bôas et al. (2003b) 29 with some modifications. Briefly, vacuum dried 
samples were resuspended in  NaOH (200 µl of a 1 M solution) and mixed with 34 µl of pyridine 
and 167 µl of methanol, followed by addition of 20 µl MCF and vortexed for 30 s carried out 
twice. Chloroform (400 µl) was added to the mixture to separate the MCF derivatives. After 
vigorous mixing, NaHCO3 (400 µl of 50 mM) was added to partition the aqueous layer. Upper 
aqueous layer was discarded and the chloroform phase was subjected to GC-MS analysis. 
GC-MS Analysis: Samples were analyzed on a Varian 450 gas chromatograph equipped with a 
Varian 220 mass spectrometer (ion trap), using a VF-5MS capillary column (30 m × 0.25 mm 
thick, 0.25 mm). Helium was used as mobile phase at 1.0 ml min-1, with a splitless injection 
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volume of 1.0 μl at 200 °C, a transfer liner at 220 °C and an ion trap at 150 °C. The mass 
spectrometer was operated in SCAN mode from 45 to 650 m/z. The column temperature was 
initially held at 45 °C for 2 min. Thereafter, the temperature was raised with a gradient of 9 °C 
min−1 until it reached 180 °C. This temperature was held for 5 min. Next, the temperature was 
raised with a gradient of 40 °C min−1 until it reached 220 °C. The temperature was again held for 
5 min. Finally, the temperature was raised with a gradient of 40 °C min−1 until it reached 240 °C, 
which was held for 11.5 min. Data handling was carried out using WORKSTATION, Version 
6.9.1 software equipped with National Institute of Standards & Technology (NIST) mass 
spectrum (MS) database. The metabolites were identified using the MS database. 
Statistical analysis 
Univariate analyses were conducted using GRAPHPAD PRISM 6.0 (GraphPad Software Inc, 
CA, USA) for Windows. Analysis of Variance (ANOVA) and Pearson’s correlation coefficients 
were performed to compare the data. All determinations were done at least in triplicate and were 
reported as means. The confidence limits used in this study were based on 95% (p < 0.05). 
Principal component analysis (PCA) was performed using SPSS Statistics 20 (IBM Corporation, 
USA) for data processing and STATISTICA 7.1 (Dell Inc., USA) for output.  
 
Results and discussion 
The two strains show similar growth patterns under laboratory and simulated in vivo conditions 
The growth curves of the organisms tested under normal laboratory conditions (30 °C, aerobic) 
and at simulated in-vivo temperature and oxygen availability (37°C, anaerobic) are shown in 
Figure 1. Both the yeast strains showed no significant difference in growth rates under the two 
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conditions (Table 1) although the maximum optical density values (ODmax) were significantly 
different between the strains under both conditions (Table 1).  The optimum doubling times (td) 
were measured at the period of maximum growth rate (k). The similar growth kinetics pattern of 
both the yeasts possibly explains why neither strain is able to colonise as a permanent part of the 
gut flora in healthy individuals and is eliminated from the system within 3-5 days after its oral 
administration is discontinued 30. The growth assessment of the two strains aided in deciding the 
sampling time points for attaining certain biomass level before carrying out the metabolome 
experiments in the later part of this study.  
 
S. cerevisiae var. boulardii is more stress tolerant than S. cerevisiae 
 
S. cerevisiae var boulardii NCYC 3264 and S. cerevisiae BY4742 showed significant difference 
in percentage viability upon heat treatment for 1 h at 37 °C (p value = 0.0078) and 39 °C (p value 
= 0.0051). Greater resistance was observed when compared to that of S. cerevisiae at both 
temperatures (Figure 2a, b). However, both the strains showed comparable decrease overtime 
with a 57.6% final viability for S. cerevisiae var. boulardii NCYC 3264 and 50.3% for S. 
cerevisiae BY4742 at 45 °C (p value = 0.0141) (Figure 2c). Viability levels under simulated 
gastric environment (pH 2.0) were indistinguishable for the first 10 min, but after 15 min, S. 
cerevisiae var boulardii NCYC 3264 appeared to be more resistant, maintaining its cell viability 
at about 57.6% with S. cerevisiae BY4742 falling to about 32% after 60 min (p value = 0.0037) 
(Figure 2d). Exposure to the simulated intestinal environment (pH 8.0) showed a slight 
difference in percentage viability (p value = 0.0419) for both the strains with a final value of 
39% and 32.3% for S. cerevisiae var boulardii NCYC 3264 and S. cerevisiae BY4742 
respectively (Figure 2e). S. cerevisiae var boulardii NCYC 3264 also exhibited a higher 
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tolerance than S. cerevisiae BY4742 for the bile tolerance assay (Figure 3). Studies with 
Bifidobacterium spp. probiotic strains show resistance to cholate concentration from 0.125 to 
1.2% 31. Other published literature suggest 0.3% as the minimum concentration to define an 
organism as resistant to bile salts 32 and the majority of yeast species grow in the presence of 
0.75% bile salts. This study partly conforms with these observations with a sensitivity of S. 
cerevisiae var boulardii NCYC 3264 at 1% cholate concentration at both 30°C and 37°C but S. 
cerevisiae BY4742 being sensitive to 0.5% cholate at both the temperatures (Figure 3).  
Interestingly, a counter observation was made by Fietto et al with no impact on cell viability of 
both S. cerevisiae var boulardii and S. cerevisiae by the simulated intestinal environment and 
both the strains showing sensitivity to bile salt concentrations more than 0.1-0.15% 33. This study 
did not specify the growth stage studied (and it is not clear which growth stage, if any, most 
closely recapitulates the prevalent phase in the mammalian gut) whereas our study used mid-log 
phase cells.  Potential differences such as this in the experimental procedures might account for 
the apparent discrepancy in the results.  
 
S. cerevisiae var boulardii demonstrates antioxidant potential 
 
The TPC of cell free extracts (CFE) and ethyl acetate fractions (EAF) of S. cerevisiae var 
boulardii NCYC 3264 were found to be significantly higher (~ 70 fold) than those of S. 
cerevisiae BY4742 (Table 2). A similar pattern was observed for the DPPH radical scavenging 
activity with the percentage inhibition of the DPPH radical in the order of BHT (control) > CFE 
of S. cerevisiae var boulardii > EAF of S. cerevisiae var boulardii > CFE of S. cerevisiae > EAF 
of S. cerevisiae (Table 2). The total flavonoid content for both the extracts of S. cerevisiae var 
boulardii were ~20-fold higher than that of S. cerevisiae BY4742 (Table 2). The TEAC values 
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were also higher in case of S. cerevisiae var boulardii with no detectable activity for both the 
extracts of S. cerevisiae (Table 2). The data suggests that S. cerevisiae var boulardii has broad 
antioxidative properties. In this study, ethyl acetate extraction of cultures was carried out as a 
means to generate polyphenol-rich fractions having bioactivities which could be attributed to 
their antioxidant properties 34, 35. A study by Pu et al also reported EAF of plant extracts as the 
fraction to demonstrate highest antioxidant activity 36. However, there was no significant 
difference between the activities shown by the CFE and EAF of S. cerevisiae var boulardii in 
this study.  
 
Multivariate analysis distinguished between S. cerevisiae var. boulardii and S. cerevisiae  
 
Principal component analysis was employed as a means of multivariate analysis in a reduced 
dimensional scaling approach to identify global similarities and differences between the two 
strains of S. cerevisiae var. boulardii NCYC 3264 and S. cerevisiae BY4742 under two different 
conditions (aerobic, 30 °C and anaerobic, 37 °C). The inter-relationship among the growth 
kinetic, probiotic and antioxidant attributes i.e. doubling time (td), maximum specific growth rate 
constant (k), viability response under heat (37 °C, 39 °C and 45 °C), simulated gastric (pH 2.0), 
intestinal (pH 8.0) and bile salt (0.5% w/v) stress and antioxidant capacity (TPC, TFC and DPPH 
radical scavenging activity), were also considered as variables in the analysis. A two-component 
construct of all the variables demonstrating a cumulative 92.97% of the total variance based on 
the eigenvalues of correlation matrix of all the components (Supplementary Table S1; 
Supplementary Figure S1) is illustrated in Figure 4 and Table 3. The first (PC1) and second 
(PC2) principal components represent 73.62% and 19.35% of the total variance respectively. 
Figure 4a and 4b depict the projection of the attributes (variables) and strains under different 
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conditions (cases) respectively. A clear separation of the probiotic and antioxidant attributes 
represented as a cluster along the X-axis from the growth kinetic parameters along the Y-axis 
was achieved (Figure 4a and Table 3a). The proximity of S. cerevisiae var. boulardii to the 
probiotic and antioxidant cluster (Figure 4b and Table 3b) clearly differentiates the strain from S. 
cerevisiae which is shown to be away from the cluster and hence negatively correlated with these 
two particular attributes. Thus, the two strains were well differentiated in the PCA supporting the 
general conclusion that they have different antioxidant profiles. 
 
Global metabolite profiling revealed antioxidant molecules  
A total of 22 metabolites in the extracellular and 18 metabolites in the intracellular fractions 
were identified in S.cerevisiae var boulardii NCYC 3264 (Table 4a) and seven metabolites in the 
extracellular and 35 metabolites in the intracellular fractions were identified in S. cerevisiae 
BY4742 (Table 4b) using a semi-qualitative analysis based on their fragmentation pattern in 
mass-spectroscopy (MS) and chromatographic retention time (Rt). The extracellular fraction of 
S.cerevisiae var boulardii NCYC 3264  demonstrated the presence of aromatic metabolites like 
phenyl ethyl alcohol (orange oil), mephaneine, cymene, hydroxycinnamic acid, cinnamic acid, 
naphthalenol (golden yellow), quinoline, erythromycin, vanillic acid and vitamin B6 in addition 
to the tricarboxylic acid cycle (TCA) metabolites such as succinate, acetate, citrate 37-39 and other 
central carbon metabolites such as amino acids and sugars (Table 4a). The intracellular fraction, 
on the other hand, contained largely intermediary central carbon metabolites (Table 4a). The 
extracellular fraction of S. cerevisiae BY4742 showed mostly TCA cycle organic acids such as 
citric acid, succinic acid, malic acid and fumaric acid along with lactic acid, glycerol and D-
glucose, which was present as the substrate in growth media (Table 4b). The intracellular 
metabolites identified were proteinogenic and non-proteinogenic amino acids, organic acids, 
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sugars, and phosphorylated sugars representing key parts of central metabolism (Table 4b). 
However, most of the intracellular metabolites identified for both the yeasts were in the low 
abundance region of the chromatogram suggesting a possible loss due to leakage of metabolites 
during sampling or insufficient cell biomass at the start of experiment 40. This study showed clear 
differences in the extracellular and intracellular metabolomes between the two yeasts with an 
abundance of aromatic metabolites in the extracellular fraction of S.cerevisiae var. boulardii 
NCYC 3264. The smaller number of central carbon metabolites in the intracellular fraction of 
S.cerevisiae var. boulardii NCYC 3264 when compared with S.cerevisiae BY4742 might be 
explained by the masking of weak intensity signals generated by the low concentrations of these 
metabolites in presence of higher concentrations of organic, inorganic acid and aromatic 
metabolites in the system. There was some overlap in the metabolites across the two 
metabolomes and between both the strains (Table 4). Some of this commonality between the 
extracellular and intracellular metabolite fractions may be partly due to the metabolic overflow 
41, 42. The pool of aromatic metabolites in the extracellular fraction of S.cerevisiae var. boulardii 
NCYC 3264 reflects the possibility of different role of these metabolites in this environment than 
inside the cell. A similar finding was reported by Granucci et al in S. cerevisiae CEN.PK113-7D 
strain where they speculated the extracellular medium as a storage place for some metabolites 
with roles other than central metabolism of the cell e.g. cell-to-cell communication, metabolic 
regulation and detoxification 42. The presence of these compounds accounts for the antioxidative 
and probiotic property exhibited by S.cerevisiae var. boulardii NCYC 3264. However, it remains 
unclear what the benefits of producing such a large range of antioxidant molecules to this strain 
are.  Nevertheless, the data indicate the possibility of exploring the potential of producing these 
metabolites on a larger, industrial scale from this strain.  
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Conclusions 
This study addressed the characterization of S. cerevisiae var. boulardii NCYC 3264 in 
comparison with S. cerevisiae with respect to probiotic and antioxidant properties.  The two 
strains are markedly different in these properties, despite close genetic similarities. Based on this 
dataset, a global screening of the metabolite profiles was performed for the two strains which 
revealed a variety of polyphenolic metabolites e.g. vanillic acid, cinnamic acid, phenyl ethyl 
alcohol, erythromycin and pyridoxine (vitamin B6).  Many of these compounds have antioxidant 
properties and are likely to contribute to the previously reported probiotic nature of S. cerevisiae 
var boulardii. In addition, some have potential commercial significance as fragrances, aroma and 
flavour compounds in food and cosmetic industries in addition to their therapeutic value. For 
example, vanillic acid has been associated with a number of pharmacological activities (such as 
inhibiting snake venom 43, 44, hepatoprotective activity 45 and apoptosis 46, 47) but its main 
application is for its pleasant creamy odour and taste leading to its widespread use in fragrances 
and licensing as a food additive (FAO/WHO Expert Committee on Food Additives, JECFA no. 
959). Cinnamic acid is used mainly in manufacturing methyl, ethyl, and benzyl esters for the 
perfume and flavour industry and is a precursor molecule for manufacturing sweetener aspartame 
via enzyme-catalysed amination to phenylalanine 48. Phenyl ethyl alcohol or rose oil (PEA) is an 
aromatic alcohol used as an ingredient in favour and perfumery particularly where the aroma of 
rose is desired 49. There have been reports on production of PEA from a thermotolerant strain of 
S. cerevisiae (Ye9-612), highlighting the commercial potential of this metabolite 50. 
Erythromycin is a potent 14-membered macrolide antibiotic active against pathogenic Gram-
positive bacteria 51, 52. Pyridoxine (vitamin B6) is manufactured as oral supplements in the 
pharmaceutical sector which is necessary for the activation of glycine in the initial stages of 
heme production in vivo 53 and is prescribed to treat a number of illnesses and deficiency 
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symptoms such as sickle-cell anemia and nervous disorders like Carpal-Tunnel syndrome 54-56. 
The detection of these bioactive compounds in the metabolite fingerprints of the extracellular 
metabolome of S. cerevisiae var. boulardii suggests the possibility of using the strain for 
industrial scale production of these metabolites.  However, before the viability of this can be 
fully assessed an in-depth biochemical study to elucidate the pathways (including key enzymes 
and intermediates) is required. Taken together, this study paves the path to understanding why S. 
cerevisiae var. boulardii is physiologically and metabolically different from baker’s yeast in 
spite of its similar genetic make-up and provides a useful “baseline” for the assessment of any 
potentially probiotic yeasts discovered in the future.  The data may also be useful in comparative 
studies between the various commercial preparations of S. cerevisiae var. boulardii which are 
sold worldwide allowing an assessment of the effects of formulation, storage etc on their 
probiotic properties. 
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Table1. Comparison of maximum specific growth rates (k), optimum doubling times (td) and maximum optical density (ODmax) of 
microwell cultures under different conditions.  
 
Values of k and ODmax were determined using non-linear curve fitting (see Materials and Methods).  Only the first 750 min were fitted due to the 
decline in optical density after this time in some cultures.  
*Statistically significantly different (p<0.05) 
 
 
 
 
Strain Laboratory conditions 
(Aerobic, 30 °C) 
 Simulated in vivo conditions  
(Anaerobic, 37 °C) 
 k (min-1) td (min) ODmax  k (min-1) td (min) ODmax 
S. cerevisiae var. boulardii (NCYC 3264) 0.0142 ± 0.0003 
 
 
48.81 1.1660 ± 0.0066 
 
 
 0.0152 ± 0.0004 
 
 
45.60 1.0590 ± 0.0072 
 
 
S. cerevisiae S288C (BY4742) 0.0143 ± 0.0004 
 
48.47 0.7349 ± 0.0056* 
 
 
 0.0145 ± 0.0005 
 
48.80 0.6421 ± 0.0062* 
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Table 2. Comparison of antioxidant properties of S. cerevisiae var.boulardii (NCYC 3264) and 
S. cerevisiae S288C (BY4742).  
Activity S. cerevisiae var.boulardii (NCYC 3264) S. cerevisiae S288C (BY4742) 
 Cell-free extract Ethyl acetate fraction Cell-free extract Ethyl acetate fraction 
TPC (mg GAE.g-1) 7.11 ± 0.30 7.05 ± 0.25 0.14 ± 0.05* 0.06 ± 0.08* 
TFC (mg QE.g-1) 0.10 ± 0.04 0.11 ± 0.20 0.006 ± 0.004* 0.004 ± 0.006* 
DPPH assay (% 
Inhibition) 
33.16 ± 0.11 28.49 ± 0.20 5.28 ± 0.30* 3.62 ± 0.41* 
TEAC (µM) 141.89 ± 0.22 144.86 ± 0.31 - a - a 
a No detectable activity 
*Statistically significantly different (p<0.05) from S. cerevisiae var.boulardii (NCYC 3264) 
TPC, total phenolic content; TFC, total flavonoid content; DPPH, scavenging activity of 1,1-
diphenyl-2-picrylhydrazyl, TEAC, trolox equivalent antioxidant capacity assay.  For assay 
conditions etc, see Materials and Methods. 
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Table 3. Component matrix of correlation coefficients of (a) variables and (b) cases on 2-
component plane extracted from principal component analysis (PCA).  
(a) 
 
 
 
 
 
 
 
 
 
TPC, total phenolic content; TFC, total flavonoid content; DPPH, scavenging activity of 1,1-
diphenyl-2-picrylhydrazyl.  For assay conditions etc, see Materials and Methods. 
(b) 
 
 
 
 
 
Variables  
Component
1 2 
Maximum sp. growth rate 
constant (k) 
.084 -.935
Doubling time (td) -.434 .895 
Heat stress (37) .981 .157 
Heat stress (39) .977 .208 
Heat stress (45) .891 .429 
Gastric stress (pH 2.0) .970 .061 
Intestinal stress (pH 8.0) .806 .298 
Bile salt stress (0.5% w/v) .941 -.171
Antioxidant capacity 1 (TPC) .944 -.164
Antioxidant capacity 2 (TFC) .951 -.227
Antioxidant capacity 3 (DPPH) .960 -.042
Cases Component 
 1 2 
S. cerevisiae var. boulardii NCYC 3264 (aerobic, 30°C) 30.13494 36.13039 
S. cerevisiae BY4742 (aerobic, 30°C) 5.94069 4.11739 
S. cerevisiae var. boulardii NCYC 3264 (anaerobic, 37°C) 15.34723 59.65203 
S. cerevisiae BY4742 (anaerobic, 30°C) 48.57714 0.10019 
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Table 4. List of metabolites identified by GC-MS  in the extracellular and intracellular fraction of (a) S.cerevisiae var boulardii NCYC 
3264 and (b) S. cerevisiae BY4742 culture. Rt =  retention time in min,  MCF = Methyl chloroformate, m/z = mass to charge ratio of 
target ion in the spectrum   
(a) 
Peak 
no. 
Extracellular fraction  Intracellular fraction 
Rt 
(min) 
Metabolite  MCF derivatives m/z 
(a.m.u) 
 Rt 
(min) 
Metabolite  MCF derivatives m/z 
(a.m.u) 
1. 8.902 Succinic acid Dimethyl ester 146  8.915 Succinic acid Dimethyl ester 146 
2. 9.222 D-glucose 2,3,6-tri-o-methyl 
ester 
222  10.786 L-alanine N-
methoxycarbonyl- 
ethyl ester 
175 
3. 9.427 1,3-dioxolane 2-methoxymethyl-
2,4,5-trimethyl-ester 
160  11.782 Hydroxylamine - 173 
4. 10.446 Phenyl ethyl alcohol 
(rose oil) 
- 122  12.615 M-cymene Methyl ester 190 
5. 10.594 Amphetamine N-methoxy carbonyl 
ester 
193  13.992 L-leucylglycine N-
methoxycarbonyl-
methyl ester 
260 
6. 10.937 2-pentenoic acid 4-methyl- ester 128  14.315 L-phenylisoquinoline - 205 
7. 11.477 Benzeneacetic acid 
(mephaneine) 
4-methyl ester 150  14.757 L-proline N-
methoxycarbonyl-
ester 
257 
8. 12.621 M-cymene Methyl ester 190  14.773 D-proline,  N-
methoxycarbonyl-
ester 
187 
9. 13.095 Hydroxycinnamic 
acid 
Methyl ester 164  14.888 Hydroxylamine - 173 
10. 13.992 L-leucylglycine N-methoxycarbonyl-
methyl ester 
260  15.495 DL-aspartic acid N-acetyl-dimethyl 
ester 
203 
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(b)
 
 
 
 
11. 15.495 DL-aspartic acid N-acetyl-dimethyl 
ester 
203  15.809 Citric acid Trimethyl ester 234 
12. 10.594 Amphetamine N-methoxy carbonyl 
ester 
193  16.206 Pyruvic acid Methyl ester 174 
13. 15.805 Citric acid Trimethyl ester 234  16.438 2,4-bis(1,1-
dimethylethyl)-phenol 
(antioxidant no. 33) 
- 206 
14. 16.540 Cinnamic acid Methyl ester 162  16.571 L-alanine  Methyl ester 317 
15. 16.571 L-alanine  Methyl ester 317  17.764 Quinoline Methyl ester 235 
16. 16.654 Acetic acid  methyl ester 214  19.871 L-phenylalanine Methyl ester 297 
17. 17.503 2,4-dinitro-1-
naphthalenol (golden 
yellow) 
- 234  26.135 Fumaric acid Dimethyl ester 245 
18. 17.518 Quinoline Methyl ester 235  29.613 Malic acid Trimethyl ester 233 
19. 17.929 Erythromycin - 733      
20. 18.679 Vanillic acid Methyl ester 182      
21. 19.871 L-phenylalanine Methyl ester 297      
22. 23.890 Vitamin B6 Methyl acetate 295      
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Peak no. Extracellular fraction  Intracellular fraction 
Rt (min) Metabolite  MCF derivatives m/z (a.m.u)  Rt (min) Metabolite MCF derivatives m/z (a.m.u) 
1. 12.102 D-glucose Dimethyl ester 146  16.206 Pyruvic acid Methyl ester 174 
2. 15.805 Citric acid Trimethyl ester 234  18.932 L-alanine Dimethyl ester 116 
3. 16.113 Lactic acid Dimethyl ester 191  22.265 Valine Dimethyl ester 144 
4. 23.952 Succinic acid  tetramethyl ester 247  23.704 Ethanolamine Dimethyl ester 174 
5. 24.062 Glycerol Trimethyl ester 218  23.986 Isoleucine/leucine Dimethyl ester 158 
6. 25.982 Fumaric acid Dimethyl ester 245  24.068 Glycerol Trimethyl ester 218 
7. 27.624 Malic acid Trimethyl ester 233  25.034 Glycine Dimethyl ester 102 
8.      25.1 Succinic acid  tetramethyl ester 247 
9.      25.817 Uracil Dimethyl ester 241 
10.      26.135 Fumaric acid Dimethyl ester 245 
11.      26.243 Serine Trimethyl ester 204 
12.      26.992 Threonine Trimethyl ester 218 
13.      28.647 Homoserine Trimethyl ester 218 
14.      29.613 Malic acid Trimethyl ester 233 
15.      30.004 Erythritol 4-methyl ester 217 
16.      30.092 Cytosine Dimethyl ester 254 
17.      30.501 Aspartate Trimethyl ester 218 
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18.      31.906 Α-ketoglutaric acid Dimethyl ester 198 
19.      32.903 Glutamate Trimethyl ester 246 
20.      33.102 Phenylalanine Dimethyl ester 192 
21.      33.419 Ribose 4-methyl ester 217 
22.      33.902 Asparagine Trimethyl ester 231 
23.      35.264 2-aminoadipic acid Trimethyl ester 260 
24.      35.802 Orotic acid Trimethyl ester 254 
25.      36.051 Glycerol-1-phosphate 4-methyl ester 370 
26.      36.452 Glutamine Trimethyl ester 156 
27.      36.742 N-acetyl-glutamic acid Dimethyl ester 216 
28.      37.312 Citric acid 4-methyl ester 273 
29.      37.506 Ornithine 4-methyl ester 258 
30.      39.311 Lysine 4-methyl ester 230 
31.      39.842 Mannitol Hexamethyl ester 307 
32.      40.002 Tyrosine Trimethyl ester 218 
33.      42.946 Inositol Hexamethyl ester 305 
34.      43.005 Xylulose-5-phosphate 5-methyl ester 315 
35.      46.821 Glucose-6-phosphate Hexamethyl ester 387 
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Table S1. Eigenvalues for each component explaining the total variance displayed after principal component analysis. 
 
 
 
 
 
Component Initial Eigenvalues Extraction Sums of Squared Loadings Rotation Sums of Squared Loadings 
Total % of 
Variance 
Cumulative 
% 
Total % of 
Variance 
Cumulative 
% 
Total % of 
Variance 
Cumulative 
% 
1 8.098 73.619 73.619 8.098 73.619 73.619 7.866 71.513 71.513 
2 2.128 19.349 92.968 2.128 19.349 92.968 2.360 21.455 92.968 
3 .774 7.032 100.000       
4 3.739E-016 3.399E-015 100.000       
5 2.486E-016 2.260E-015 100.000       
6 9.181E-017 8.347E-016 100.000       
7 8.614E-017 7.830E-016 100.000       
8 1.653E-018 1.502E-017 100.000       
9 -1.134E-016 -1.031E-015 100.000       
10 -2.253E-016 -2.048E-015 100.000       
11 -4.340E-016 -3.946E-015 100.000       
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